World Health Organization

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
Friday, April 26, 2024
COVID-19, Public Policy, Other Policy Issues, Healthcare Reform, Pharmaceutical, Social Activism, Communications, General Health, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Foundation, AIDS, Health, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement.

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement.
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

Latin America CDC a Must, say Public Health Leaders and AHF

Retrieved on: 
Friday, April 26, 2024
COVID-19, Infectious Diseases, Hospitals, Hispanic, Other Health, Managed Care, Health, Consumer, General Health, Mark R. Dybul, Public, University, Pandemic, AIDS, Safety, Public health, World Health Organization, Policy, CDC, Dengue fever, AH1N1, Infection, LATAM, Research, Vaccine, Cayetano Heredia University, Emergency, AIDS Healthcare Foundation, Acquisition, Data collection, Private sector, Death, Faculty, AHF, Lancet

This new agency would seek to strengthen regional resilience against future health crises through collaboration and resource optimization among nations.

Key Points: 
  • This new agency would seek to strengthen regional resilience against future health crises through collaboration and resource optimization among nations.
  • Patricia J. Garcia, former health minister of Peru, principal professor of the Faculty of Public Health of the Universidad Peruana Cayetano Heredia, and one of the initiative's proponents, emphasized the importance of this regional collaboration: "The experience with COVID-19 demonstrated critical deficiencies in our public health infrastructure.
  • The LATAM CDC will serve as a fundamental pillar for prevention, preparedness, and rapid response to future health emergencies, thus strengthening our regional health sovereignty."
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

Recce Pharmaceuticals Provides Business Update

Retrieved on: 
Wednesday, April 10, 2024
Urine, FDA, Congress, Multi, WHO, Ecosystem, Safety, World Health Organization, Blood, Food, Burn, Poster, Infection, AMR, Partnership, Recce, Escherichia coli, Fungal infection, Research, Sputum, BIO, Development, IND, Pharmacology, Defense, Science, Society, MDR, Clinical trial, Annual general meeting, Antimalarial medication, Government, Therapy, Biotechnology, Investigational New Drug, Sepsis, Pharmaceutical industry

These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly.

Key Points: 
  • These achievements collectively position Recce on track with its upcoming IND application, underscoring the company's dedication to bringing novel therapies to market swiftly and responsibly.
  • Recce has been actively pursuing various grant applications and submissions, particularly in government antimicrobial resistance (AMR) initiatives and military and health security.
  • Recce delivered a company presentation at the request of the U.S. Biomedical Advanced Research and Development Authority (BARDA), further strengthening its relationship and collaboration with U.S. governmental organizations.
  • This acknowledgment highlights the potential of RECCE® compounds to address critical global health challenges posed by antibiotic-resistant bacteria.

Oncology Precision Medicine Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Pharmaceutical, Health, Oncology, Molecule, USD, Mortality, Radiation, Volunteering, Administration, Breast cancer, Cancer, Lung cancer, World Health Organization, Hub, Risk, Immunotherapy, Research, Genetic testing, Obesity, Disease, DNA, Therapy, Oncogene, Patient, Gastrointestinal cancer, Bone marrow, MD Anderson Cancer Center, Clinical trial, Medicine, Viral, Type, Interest, Mayo Clinic Cancer Center, Growth, Prevalence, Medical imaging

The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.

Key Points: 
  • The growth in the oncology precision medicine market size over the next decade is likely to be the result of an anticipated increase in patient population and rise in the demand for personalized medicine in oncology for precision cancer care.
  • Regional Analysis: North America Emerged as the Hub of Oncology Precision Medicine; Europe to be the Fastest Growing Market
    In 2024, North America is anticipated to capture close to 42% market share of the overall oncology precision medicine market.
  • In recent years, demand for oncology precision medicine has witnessed a tremendous increase in North America.
  • The oncology precision medicine market report presents an in-depth analysis of various precision medicine oncology companies in this domain, across different segments, as defined below:

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
Wednesday, April 24, 2024
COVID-19, Infectious Diseases, Public Policy, Government, AIDS, Health, Pharmaceutical, General Health, Other Policy Issues, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024 , Proposal for the WHO Pandemic Agreement.

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024 , Proposal for the WHO Pandemic Agreement.
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Retrieved on: 
Wednesday, April 24, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neisseria gonorrhoeae, Gonorrhea, Randomized controlled trial, World Health Organization, Safety, Woman, ToC, Heart, Ceftriaxone, AMR, ESCMID, Partnership, Zoliflodacin, Azithromycin, Patient, Physician, IM, Failure, HIV, Infection, Clinical trial, Therapy, Organization, Prevalence, Cohort (statistics), Pharmaceutical industry

Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.

Key Points: 
  • Zoliflodacin is a first-in-class spiropyrimidinetrione, single dose, oral antibiotic that is being developed in partnership with GARDP for the treatment of uncomplicated gonorrhea.
  • GARDP and Innoviva Specialty Therapeutics plan to submit the Phase 3 zoliflodacin data for future publication in a medical journal.
  • Oral zoliflodacin 3g was generally well tolerated and emergent adverse events were comparable between treatment arms (46.2% vs 46.4%).
  • Details for the ESCMID Global 2024 presentations are as follows:
    Title: Oral zoliflodacin is non-inferior to a combination of ceftriaxone and azithromycin for treatment of uncomplicated urogenital gonorrhoea: results of a large global Phase 3 randomized controlled trial
    Session: 05.

New Pandemic Agreement: Pharma Wins, Developing World Loses, says AHF Global Public Health Institute

Retrieved on: 
Wednesday, April 24, 2024
Public Policy, Government, Pharmaceutical, AIDS, General Health, Health, Other Policy Issues, Infectious Diseases, Advocacy Group Opinion, United Nations, Public, University, IHR, PABS, Language, WHO, Community of practice, Learning, Pandemic, World Health Organization, INB, Policy, Infection, Intergovernmental, Conference, Research, Vaccine, Hoarding, Literature, International Health Regulations, AIDS Healthcare Foundation, Panel, Global health, Secretariat, AHF, United Nations General Assembly, Lancet, COVID-19, Letter, Pharmaceutical industry

As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement .

Key Points: 
  • As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the April 16, 2024, Proposal for the WHO Pandemic Agreement .
  • In addition to the GPMB and the IPPPR, the Panel for a Global Public Health Convention and Spark Street Advisors have also emphasized the critical need for independent monitoring.
  • Empty handshakes in Geneva will not prevent another global health disaster, nor will it keep countries from trampling over each other when the next pandemic comes.
  • To learn more about the AHF Global Public Health Institute, visit https://ahfinstitute.org/ .

$3.84 Bn Biopsy Devices Market, Size, Global Forecast Report 2024-2030 Featuring Cardinal Health, Hologic, Danaher, BD and Co, Boston Scientific, Medtronic, Olympus, and CONMED - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 23, 2024
Health, Oncology, Medical Devices, Insight, Cancer, WHO, Magnetic resonance imaging, World Health Organization, Prostate biopsy, Woman, Research, Trauma, Traction, Lung biopsy, Needle, Attention, Disease, Biopsy, Infection, Diagnosis, Breast biopsy, Liver biopsy, Medical imaging

The increasing occurrence of cancers globally drives growth within the biopsy devices market.

Key Points: 
  • The increasing occurrence of cancers globally drives growth within the biopsy devices market.
  • Innovations like Vacora, Finesse Ultra Breast Biopsy System, and Celero VAB gadgets will bolster the boom trajectory of the biopsy devices market.
  • The biopsy devices market is segmented based on application into Breast Biopsy, Lung Biopsy, Prostate Biopsy, Liver Biopsy, Gastroenterology Biopsy, and Others.
  • Due to their superior imaging technologies and specialized information, diagnostic and imaging facilities are among the segments gaining traction within the global biopsy devices market.

Rising Malaria Threat: International SOS Shares Advice on How to Keep Your Workforce Healthy

Retrieved on: 
Tuesday, April 23, 2024
Technology, Mobile, Wireless, Other Travel, Health, Human Resources, Travel, Other Transport, Other Health, Consulting, Banking, Professional Services, Transport, Other Technology, Data Management, Education, Climate change, RTS, International, WHO, Diagnosis, World Health Organization, Risk, Insecticide, Parasitism, Death, Entomology, Life, Occupational medicine, NGO, Global Health, International SOS, Data management, Workforce, Non-governmental organization, Private sector, Mining, Fever, Infection, Vaccine

International SOS global assistance data reports a 15% increase in malaria-related assistance requests in 2023 compared to 2022.

Key Points: 
  • International SOS global assistance data reports a 15% increase in malaria-related assistance requests in 2023 compared to 2022.
  • It is predicted with climate change that this risk could grow, and malaria transmission could spread into countries previously free of malaria.
  • International SOS also provides consulting services for every part of a company’s malaria risk mitigation programme.
  • Join International SOS webinar ‘Climate Change and Malaria: Navigating the Global Health Landscape’ on 7 May, where our experts will discuss the relationship between climate change and malaria.

Warby Parker Publishes 2023 Impact Report

Retrieved on: 
Wednesday, April 17, 2024
Fashion, Women, Environment, Retail, Other Philanthropy, Men, Children, Optical, Sustainability, Environmental, Social and Governance (ESG), Online Retail, Consumer, Professional Services, Philanthropy, Other Retail, Health, Recycling, Lifestyle, United, World Health Organization, City, Glasses, Partnership, GRI, Lions Clubs International, Lens, Government, Lion, Work, Sustainability accounting, Sustainable Development Goals, Natural Resources, Eastman Chemical Company, Organization

Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today published its 2023 Impact Report.

Key Points: 
  • Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today published its 2023 Impact Report.
  • Each year, Warby Parker tracks and reports its impact on stakeholders following the Global Reporting Initiative (GRI) framework.
  • Warby Parker also releases a Sustainability Accounting Standards Board (SASB) summary and aligns its key areas of sustainability to the United Nations’ Sustainable Development Goals (SDGs) within the Impact Report.
  • Highlights from the 2023 Impact Report include:
    Surpassing 15 Million Pairs of Glasses Distributed Through its Buy a Pair, Give a Pair Program: Warby Parker believes in vision for all, which is why for every pair of glasses or sunglasses sold, a pair of glasses is distributed to someone in need through its Buy a Pair, Give a Pair program.